Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial-Reference-Cited by-同舟云学术

Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial

Published:2023-08 Issue: Volume: Page:
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Maranda Bruno,Labbé Sébastien M,Lurquin Magali,Brabant Pascal,Fugère Alexandre,Larrivée Jean-François,Grbic Djordje,Leroux Annie,Leduc Frédéric,Finzi Andrés,Gaudreau Simon,Swart Yolandi

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference29 articles.

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China;Huang;Lancet,2020

2. SARS-CoV-2 omicron variant replication in human bronchus and lung ex vivo;Hui;Nature,2022

3. REGEN-COV antibody combination and outcomes in outpatients with COVID-19;Weinreich;N Engl J Med,2021

4. Effectiveness of casirivimab-imdevimab and sotrovimab monoclonal antibody treatment among high-risk patients with SARS-CoV-2 infection: a real-world experience;Murugapandian;medRxiv,2022

5. Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic;Nichols;Lancet Infect Dis,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhalable dry powders of a monoclonal antibody against SARS-CoV-2 virus made by thin-film freeze-drying;International Journal of Pharmaceutics;2024-09

2. An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2;Clinical Microbiology and Infection;2024-08

3. Emerging anti-spike monoclonal antibodies against SARS-CoV-2;Expert Opinion on Biological Therapy;2024-03-03

4. Identifying COVID‐19 subtypes by single‐sample gene set enrichemnt analysis and providing guidance for sensitive drug selection;Journal of Medical Virology;2024-03

5. The insights from SARS-CoV-2 antibody treatment for future emerging infectious diseases;The Lancet Infectious Diseases;2024-01